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expression may cause perturbed axonal transport and 
changes in APP processing, contributing to cognitive decline 
and neurodegeneration in Alzheimer’s disease.  
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 Subcellular Trafficking of APP/APLPs 
 The amyloid precursor protein (APP), similar to other 
typical type I transmembrane proteins, is cotranslation-
ally translocated during migration across the ER mem-
brane and remains anchored there by a single membrane 
spanning   -helical region. APP is inserted in the mem-
brane such that only a short tail remains in the cytosol, 
whereas the major N-terminal forms a relatively large ex-
tracellular domain. APP is then transported from the ER 
to the Golgi apparatus, whereby it undergoes different 
posttranslational covalent modifications, including N- 
and O-glycosylation, sialylation, and modification with 
chondroitin sulfate glycosaminoglycan and/or dermatan 
sulfate glycosaminoglycan  [1, 2] . During passage through 
the different subcompartments of the Golgi apparatus, 
APP is sorted into secretory vesicles. On its way from the 
Golgi to the plasma membrane and to endosomes, a por-
tion of APP is processed by different secretases. The ex-
tracellular domain of APP can be cleaved by   -secretase 
or, alternatively, by the   -secretase BACE 1 (  -site APP 
cleaving enzyme 1). The resulting membrane-retained
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 Abstract 
 Changes in the intracellular transport of amyloid precursor 
protein (APP) affect the extent to which APP is exposed to 
  - or   -secretase in a common subcellular compartment
and therefore directly influence the degree to which APP 
 undergoes the amyloidogenic pathway leading to genera-
tion of   -amyloid. As the presynaptic regions of neurons are
thought to be the main source of   -amyloid in the brain, at-
tention has been focused on axonal APP trafficking. APP is 
transported along axons by a fast, kinesin-dependent an-
terograde transport mechanism. Despite the wealth of in 
vivo and in vitro data that have accumulated regarding the 
connection of APP to kinesin transport, it is not yet clear if 
APP is coupled to its specific motor protein via an intracel-
lular interaction partner, such as the c-Jun N-terminal kinase-
interacting protein, or by yet another unknown molecular 
mechanism. The cargo proteins that form a functional com-
plex with APP are also unknown. Due to the long lifespan, 
and vast extent, of neurons, in particular axons, neurons are 
highly sensitive to changes in subcellular transport. Recent 
in vitro and in vivo studies have shown that variations in APP 
or tau affect mitochondrial and synaptic vesicle transport. 
Further, it was shown that this axonal dysfunction might 
lead to impaired synaptic plasticity, which is crucial for neu-
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C-terminal fragments are subsequently processed by 
cleavage within the transmembrane region by the   -secre-
tase complex  [3] .   - and   -cleavage of APP results in the 
release of amyloid-  (A  ) peptides, while   - and   -cleav-
age generate p3 fragments. Besides the Golgi apparatus, 
the plasma membrane was shown to be one of the two 
major sites where   -secretase cleavage of APP takes place 
 [4, 5] . In contrast, BACE1 is most active at mildly acidic 
pH  [6] , making endosomes the most likely location for 
BACE cleavage of APP. Moreover, BACE 1 was reported 
to cycle between the cell surface and endosomes  [7] . It was 
also shown that internalization of cell surface APP via en-
docytosis leads to elevated A  generation and subsequent 
release into the medium  [8] . Thus, changes in subcellular 
APP trafficking affect the time that APP spends together 
with   - or   -secretase in a common subcellular compart-
ment and, thereby, the APP processing.
 In particular, neurons, which have very long processes 
(the axon of human motoneurons can be up to 1 m in 
length), are dependent on an appropriate subcellular lo-
calization of transcripts and proteins which presumes a 
highly complex transport system. Due to their morphol-
ogy and long life span, neurons are highly vulnerable to 
any perturbation of their transport machinery. There is 
emerging evidence that impaired axonal transport is 
causal for different neurodegenerative disorders, includ-
ing Alzheimer’s disease (AD).
 APP is anterogradely transported in tubular vesicles 
along the axons  [9–15] with a velocity up to 10   m per 
second  [16, 17] . These transport vesicles differ from axo-
nal vesicles transporting neurotransmitters towards the 
synapse  [18] or from those much slower vesicles, trans-
porting synaptophysin along the axon  [17] . The antero-
grade transport of APP depends on kinesin-1  [2, 9, 17, 
19–22] , which consists of two kinesin heavy and light 
chains (KHC, KLC). Motor activity and specificity of car-
go binding are localized in the KHC  [23] , whereas the 
KLC is thought to regulate the motor activity and bind 
via its TPR-like motif to vesicular receptor and linker 
proteins. In mammals, there are three different KHCs: 
kinesin-1A, -1B and -1C (KIF5A, B, C)  [24–28] , and three 
KLCs  [29] , KLC1, KLC2 and KLC3. Kinesin-1A, kinesin-
1C and KLC1 are specific to neurons, whereas kinesin-1B 
and KLC2 are expressed ubiquitously  [24, 25] . The KLC3 
expression in the brain is very low, but it plays a unique 
role in the spermatids in testis  [30] . Different kinesin-1 
tetrameric heterocomplexes consisting of two KHCs and 
two KLCs may participate in selective transport by using 
adapter or scaffolding proteins to recognize and bind 
specific cargoes  [31] .
 It was proposed that APP may play a role as a kinesin 
cargo receptor  [32] , directly interacting with the motor 
protein kinesin-1, connecting it to a certain axonal vesicle 
class with specific cargo proteins, including the APP 
secretases, BACE and presinilin (PS)  [33] . A  production 
was observed in sciatic nerve extracts, indicating that 
APP may be processed in axonal transport vesicles  [33] .
 The hypothesis that the APP intracellular domain 
(AICD) interacts directly with kinesin-1 was based on 
GST pull-down analyses, showing high affinity binding 
(KD = 16–18 n M ) of GFP-AICD with GST-KLC1 and GST-
KLC2 fusion proteins. More detailed GST pull-down ex-
periments revealed that this binding was caused by a non-
specific hydrophobic interaction to the tandem repeats in 
the carboxy terminus of bacterially expressed KLC1  [34] . 
Consistent with this, GST pull-down analyses with GST-
AICD and recombinant KLC1 expressed in mammalian 
cells revealed no specific interaction, whereas other known 
interaction partners of APP, such as Fe65 or Numb, were 
specifically retained on beads loaded with GST-AICD. To-
gether, these data strongly suggest that KLC1 does not in-
teract directly with the cytoplasmic tail of APP. Nonethe-
less, KLC1 and KLC2 appear to be associated with differ-
ent subsets of APP-containing membrane compartments 
[S.K., pers. obs.;  32 ]. Thus, an indirect interaction of APP 
with kinesin via a cytosolic APP interaction partner could 
be postulated. However, coimmunoprecipitation studies 
of APP and kinesin-1 from mouse brain lysates with any 
of a wide range of specific antibodies to different epitopes 
on KLC, KHC, and APP N- and C-terminus (kindly ob-
tained from G. Multhaup, Berlin, and T. Hartmann, Hei-
delberg) [ 34 ; S.K., pers. commun.] revealed, in contrast to 
previous studies from Kamal et al.  [32] , no indication for 
a common complex of APP and kinesin. Importantly, oth-
er putative kinesin-cargo receptors, such as JIP3/JSAP1 
(Sunday driver, Syd)  [35] , have been coimmunoprecipi-
tated under identical conditions  [34] . Nevertheless, based 
on the negative results from the in vitro binding studies 
and coimmunoprecipitation studies, an indirect associa-
tion of APP to kinesin-1 via an AICD interacting protein 
cannot be excluded.
 Different linker molecules are known that connect a 
specific motor protein to a certain class of vesicles. For 
example,   1 adaptin was reported to couple KIF13A, a 
plus end-directed microtubule-dependent motor protein, 
to the AP-1 adaptor complex and mannnose-6-phosphate 
receptor  [36] . Other linker proteins are scaffolding pro-
teins that are capable of interacting with a set of different 
interaction partners and which often cluster functional 
complexes, such as PSD-95  [37] , glutamate-receptor-in-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 1
2:
34
:3
2 
PM
 Kins/Lauther/Szodorai/Beyreuther
 
Neurodegenerative Dis 2006;3:218–226220
teracting protein 1  [38–42] , X11 (LINs, MINT)  [43, 44] , 
Syd, a c-Jun N-terminal kinase (JNK)-interacting protein 
(JIP )  3 homologue in  Drosophila or JIP1b and JIP2  [34, 
35, 45–51] ( table 1 ).
 X11 and JIP1b/2 have a phosphotyrosine interaction/
binding domain  [52–54] that interacts with the NPTY 
motif of AICD. Thus, they may couple APP-containing 
vesicles to a certain signaling pathway by creating a scaf-
fold  [52–54] and may link APP to a special type of kinesin 
transport. Considering that APP is driven with different 
velocities (2–10   m/s), the different linker proteins may 
couple APP to different kinesin transport complexes with 
different velocity characteristics. Each of these adapter 
proteins could represent the unknown linker protein for 
a specific subset of vesicles.
 Based on in vitro analyses it was proposed that JIP-1b 
might connect APP-bearing axonal vesicles to the kine-
sin-1 motor mechanism  [46, 47, 50] . To test this proposal 
in vivo, we performed APP/JIP1b coimmunoprecipitation 
studies and analyzed the subcellular transport of APP in 
primary neurons treated with specific siRNA to knock-
down JIP-1b/2. Under conditions that allowed specific co-
immunoprecipitation of complexes containing APP and 
APLP1 or APLP2  [55] , coimmunoprecipitation of APP 
and JIP-1b was not observed. However, these data do not 
exclude a role of JIP-1b as a linker of APP to the transport 
machinery, which might require only a transient, low af-
finity binding. To address the influence of JIP1b on APP 
trafficking more directly, we screened different siRNAs 
directed against JIP1b and found that in mixed cortical 
primary neurons (DIV11) a knockdown of endogenous 
JIP-1b to less than 5% of the endogenous level ( fig. 1 ) was 
observed after siRNA treatment. Immunocytochemical 
analyses of wild-type neurons with anti-JIP1b antibodies 
revealed that endogenous JIP1b accumulated at the tips of 
the neurites ( fig. 2 a–c). In JIP-1b  knockdown neurons, no 
specific JIP1b immunoreactivity was detected ( fig. 2 d–e). 
Surprisingly, costaining of JIP-1b siRNA-treated neurons 
with anti-APP antibodies revealed that APP was localized 
not just in the perinuclear region, but also at the tips of 
neurites, showing that APP can be anterogradely trans-
ported in the absence of JIP1b ( fig. 2 d, f). These data are 
consistent with the results from a recent study, showing 
that the majority of APP does not colocalize with JIP-1b 
and that a knockdown of JIP1b only has an influence on 
transport of the minor pool of APP phosphorylated at 
Table 1. Different linker molecules connect specific motor protein to certain class of vesicles
Motorprotein Motorprotein new
nomenclature [28]
Linker Cargo References
KHC Kinesin-1 Syntabulin- Syntaxin-1, mitochondria [84, 85]
KIF5 Kinesin-1 GRIP1 AMPA receptor [38, 40]
KIF5 Kinesin-1 JIP1,2,3 (MAPK8IP1, 2, 3) JNK signaling cascade (DLK), ApoER2 [34, 35, 45–51]
KIF3A Kinesin-2 – Opsin, arrestin [86]
KIF3, KAP Kinesin-2 – Chromosomes, flagellar cargoes [87–90]
KIF13A Kinesin-3 AP-1 clathrin, M6PR [36]
KIF17 Kinesin-3 X11 (mLIN-10, MINT) mLIN-2 (CASK), mLIN-7 (VELIS/
MALS), NMDAR (NR2B subunit)
[43, 44]
KIF1A Kinesin-3A Liprin-, (PPFIA2) GRIP, AMPAR, RIM, GIT1, PIX, 
synaptic vesicles
[39, 41, 42, 91]
KIF1B Kinesin-3B PSD-95 (SAP90) PSD-95, synaptic precursor vesicles [37, 92]
PPFIA2 = Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein 2; PSD-95 = postsynaptic density 95; 
SAP90 = synapse-associated protein 90; GRIP1 = glutamate receptor-interacting protein 1; AP-1 = adaptor protein 1; mLIN-10 = ver-
tebrate LIN10 homolog; MINT = MUNC18-1-interacting protein; NMDAR = N-methyl-D-aspartate receptor; CASK = calcium/
calmodulin-dependent serine protein kinase; AMPA = -amino-3-hydroxy-5-methyl-4-isoxazolpropionate; GRK = G-protein-cou-
pled receptor kinase; GIT1 = GRK-interacting protein 1; PAK = p21-activated kinase and phospholipase C-interacting protein 1;
PIX = PAK-interacting exchange factor; M6PR = mannnose-6-phosphate receptor.
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threonin 668  [49] . Altogether, it is clear that APP does not 
bind directly to kinesin and that JIP1b is not the main 
linker that couples APP to the anterograde transport ma-
chinery ( fig. 3 ). However, further analyses are necessary 
to determine the molecular link between APP and the ki-
nesin motor mechanism.
 The molecular composition of APP/APLPs-contain-
ing vesicles also remains unclear. BACE and PS1 are 
transported along the axon  [56, 57] and, as mentioned 
before, Kamal et al. [33] proposed that these two APP 
secretases are specific cargoes of APP-containing vesicles 
transported by the fast anterograde transport machinery. 
However, careful studies assessing the trafficking of 
membrane proteins in the sciatic nerves of mice with het-
erozygous or homozygous deletions of APP show that the 
axonal transport kinetics of BACE and PS1 are different 
from APP and that they are unchanged in APP knockout 
mice  [34] . These data argue that the APP-processing ap-
paratus is transported in TGN vesicles different from 
those that transport APP, suggesting axonal processing 
of APP by BACE and the   -secretase complex takes place 
at the plasma membrane or endosomes. However, it is not 
clear whether   -secretase might be cotransported with 
APP. Other proposed cargo proteins cotransported with 
APP have not been verified in subsequent studies  [33, 
34] .
 In recent studies from our laboratory, we determined 
that APP, APLP1 and APLP2 not only have very similar 
structures, but also form homo- and heterotypic com-
plexes, suggesting a close functional relation between the 
APP gene family members  [55] . This view is also sup-
ported by genetic analyses of the APP gene family  [58, 
59] and studies addressing the influence of APLP1 and 
APLP2 on APP processing  [60] . We could show in exten-
sive coimmunoprecipitation studies that both mature 
and immature APP/APLPs can interact with similar ef-
ficiency  [55] . This observation is consistent with studies 
showing in vitro dimerization of recombinantly ex-
pressed soluble APP  [61] . However, we found that endog-
enous heterocomplexes contain exclusively mature APP/
APLPs. Moreover, these high molecular weight species of 
APP family interacting proteins strongly accumulate in 
synaptic plasma membrane fractions  [55] . As only ma-
ture APP is present at the cell surface  [62] , we favor a 
model in which endogenous APP/APLP heterointerac-
tion in the brain is limited to the cell surface, which 
would allow transcellular binding. APP and APLP2 have 
previously been shown to be transported to presynaptic 
terminals  [1, 10] and growth cones of neurons  [63] , while 
APLP1 has been reported to localize to the postsynapse 
terminals  [64] . Interestingly, all APP family members 
exhibit developmentally increased expression levels cor-
relating with postembryonic synaptogenesis  [13, 65, 66] , 
and recent genetic analyses in mouse and  Drosophila re-
vealed that the APP gene family members are required 
for neuromuscular synaptogenesis  [67, 68] . Together 
with our data, these findings indicate that transcellular 
APP/APLP interaction is part of the regulation of synap-
togenesis. In regard to the different subcellular localiza-
tions of APP, APLP1 and APLP2 in neurons  [1, 64] , it is 
reasonable that APP, APLP1 and APLP2 are transported 
in different types of vesicles and are differently coupled 
to specific anterograde transport mechanisms. In prin-
ciple, each subtype of transport vesicle is thought to me-
diate the axonal/dendritic transport of a specific set of 
functional protein complexes  [69, 70] . Thus, it will be of 
130
100
55
– + – + – +
JIP1b
siRNA-JIP1b
kDa
+ + + + + +JIP1b
6 h 18 h 26 h
-Tubulin
 Fig. 1. JIP-1b knockdown in primary neu-
rons. Mouse primary neurons (DIV11) 
were transfected with JIP-1b cDNA only or 
simultaneously treated with 40 n M siRNA 
against JIP1b. Expression of JIP1b was 
evaluated 6–24 h after transfection. The 
cells were lysed and subjected to PAGE
and Western blot analyses using anti-
JIP-1b [1:  500] antibody. Anti-  -tubulin
[1:  10,000] antibody was used as a loading 
control. Efficient knockdown of JIP-1b oc-
curs after 18 h up to 24 h. 
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great interest to elucidate the molecular composition of 
the specific transport vesicle types transporting APP, 
APLP1 and APLP2. These analyses will also allow con-
clusions regarding their specific molecular function 
( fig. 3 ).
 Pathogenic Role of the APP Gene Family in Axonal 
Transport 
 In addition to the importance of interactions between 
APP and its processing machinery during transport, an-
other potential important role of APP in axonal transport 
was shown in studies of  Drosophila wandering third in-
star larvae with a deletion of the APPL gene (the  Dro-
sophila homologue of APP) or overexpressing APP/APPL. 
Changes in the dose of APP/APPL resulted in increased 
accumulation of synaptic vesicles in peripheral axons – a 
phenotype also observed in JIP 1/2 (APLIP1)  or JIP3/
JSAP1 (Syd) mutant Drosophila larvae  [35, 46, 71] . JIP1 
and JIP2 – as well as JIP3, although very different in pri-
mary sequence – belong to a family of scaffold factors for 
the mitogen-activated protein kinase (MAPK) cascades, 
and accumulate at the leading edges of cells  [72–74] . Mu-
tation of APLIP1 caused axonal transport defects of both 
anterograde and retrograde vesicle transport. Thus, 
APLIP1 may be an important part of motor-cargo link-
age complexes for kinesin-1 and dynein. Alternatively, 
APLIP1 and its associated JNK signaling proteins may 
serve as an important signaling module in MAPK path-
way for regulating transport by the two opposing mecha-
nisms  [46, 75] . APP might function as a regulator of the 
scaffolding activity of JIP1 in the JNK signaling pathway, 
as recently shown for the Notch intracellular domain 
 [76] .
 In a recent paper, Stokin et al. [77] identified axonal 
defects in APP transgenic mice. They found in fibers of 
the nucleus basalis of Meynert, which provide the major 
cholinergic input to the cerebral cortex, that the axonal 
varicosities exhibited substantial variation in size and 
morphology. Generally, varicosities correspond to en 
passant synaptic boutons, are regularly spaced, and have 
relatively constant diameters. The varicosities in the 
transgenic mice, in contrast, were often unusually large 
and irregularly spaced and contained large numbers of 
mitochondria, sporadic multilamellar bodies, vacuoles, 
and vesicles. Varicosities of diameters larger than 3   m, 
termed swellings, were in transgenic mice three times as 
many as in controls. This is a feature suggestive of axonal 
transport defects, as found previously in tau transgenic 
mouse and  Drosophila models  [78–80] and in dystrophic 
neuritis embedded in amyloid in AD  [80, 81] . Interest-
ingly, a 50% reduction in genetic dosage of KLC1 in these 
APP transgenic mice caused a significant increase of ax-
onal swellings and A  generation preceding the onset of 
amyloid deposition, suggesting that impaired transport 
may contribute to early stages of AD  [77] .
 Recently, it was reported that transgenic expression of 
human tau (0N3R) in  Drosophila larval motor neurons 
causes morphological and functional disruption to the 
neuromuscular junctions  [80] . Despite reduction in size 
with irregular and abnormal bouton structure and ab-
normal endo-/exocytosis, tau-expressing neuromuscu-
lar junctions retain synaptotagmin expression and can 
form active zones. Electrophysiological studies showed 
that following high frequency stimulation (50 Hz), 
evoked synaptic potentials were significantly decreased 
 [80] . The mechanism underlying the change in evoked 
synaptic potentials is not clear, but might contribute to a 
significant reduction in the number of mitochondria in 
the presynaptic terminals of motor neurons expressing 
mutant tau. These results suggest that disruption of axo-
Fig. 2. The anterograde transport of APP is independent of JIP1b. 
Mouse primary neurons (DIV5) were treated with JIP1b siRNA 
( d–f ) or nonsense siRNA ( a–c ) for control. The cells were sub-
jected to immunocytochemical analyses using anti-APP ( a ,  c ,  d , 
 f ; red) and anti-JIP-1b ( b ,  c ,  e ,  f ; green) antibodies 18 h after trans-
fection. Colocalization of endogenous APP (red) and JIP1b (green) 
was detected in the cell soma and at the tips of neurites, as indi-
cated by the overlap ( c ,  f ; yellow). Scale bar: 20   m (insets: 
6   m).
 Fig. 3. Model of the subcellular transport of the APP family mem-
bers. APP, APLP1 and APLP2 (APP/APLPs) are transported in 
neurons to the dendritic and axonal compartment.  a They are ca-
pable of forming homo- and heterocomplexes in a cis- and tran-
scellular fashion (1–5), promoting cell-cell adhesion. It is possible 
that the transcellular interaction takes place between pre- and 
postsynaptic membranes in neurons. Alternatively, transcellular 
interaction involving APP/APLPs may take place between neu-
rons and glia cells. APP/APLPs can be transported in common (b, 
c) or separate (a) vesicles in the form of monomers, homo- or het-
erocomplexes, towards the plasma membrane. The different di-
mer combinations and vesicle compositions may modulate the 
targeting and functions of APP/APLPs in neurons.  b Axonal 
transport of APP/APLPs is driven by kinesin-1. A part of APP/
APLPs might be coupled via JIP1b to the motor machinery (1); 
however, recent data indicate that APP/APLPs can be transported 
by kinesin in absence of JIP1b, suggesting the existence of an ad-
ditional molecular linker, coupling APP-containing vesicles to 
the kinesin motor machinery (2). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 1
2:
34
:3
2 
PM
 Kins/Lauther/Szodorai/Beyreuther
 
Neurodegenerative Dis 2006;3:218–226224
nal transport and synaptic transmission may be key 
components of the pathogenic mechanism that underlie 
neuronal dysfunction in the early stages of tauopathies. 
It will be interesting whether changes in the dose of APP/
APPL, which also affect the axonal transport of synaptic 
vesicles and morphology of synapses in mouse and  Dro-
sophila models, may also lead to altered synaptic plastic-
ity, thought to represent the neurophysiological correlate 
of learning and memory  [82, 83] . If true, this would 
strongly favor the hypothesis that changes in the dose of 
APP and tau cause altered neurotransmission, contrib-
uting to cognitive decline and neurodegeneration of 
AD.
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